Marshall Wace
TNXP icon

Marshall Wace’s Tonix Pharmaceuticals TNXP Stock Holding History

Marshall Wace’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-509
Closed -$309K – 2966
2024
Q1 		$309K Sell
509
-241
-32% -$260K ﹤0.01% 2099
2023
Q4 		$960K Buy
+750
New +$1.21M ﹤0.01% 1490

Other funds holding TNXP

Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's TNXP Position: Q2 2024 in Review

Marshall Wace sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 509 shares — an estimated $309K sold.

Marshall Wace first reported a position in TNXP in Q4 2023 and held it in 2 quarters. The position peaked at $960K in Q4 2023. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

  • Marshall Wace reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Marshall Wace sold 509 Tonix Pharmaceuticals shares in Q2 2024, an estimated $309K.
  • Marshall Wace first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Marshall Wace's Tonix Pharmaceuticals position peaked at $960K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.